Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehmet Altan

Showing results (91-100 of 153) with videos related to

Pageof 16
Sort By:
Clinical Chemistry and Laboratory Medicine|October 26, 2022
Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control studyAntigona Ulndreaj, Davor Brinc, Mehmet Altan, et al.
Journal for Immunotherapy of Cancer|October 14, 2020
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trialJames Welsh, Hari Menon, Dawei Chen, et al.
NPJ Precision Oncology|June 26, 2026
Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biologyJennifer A Marks, Rohan Maniar, Kavitha J Ramchandran, et al.
Clinical Lung Cancer|August 25, 2024
Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective AnalysisFelipe Soto-Lanza, Lydia Glick, Colin Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2021
Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II TrialYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Journal for Immunotherapy of Cancer|June 22, 2023
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitisYousef R Badran, Fangwen Zou, Sienna M Durbin, et al.
Frontiers in Immunology|March 5, 2019
Role of Radiation Therapy in Modulation of the Tumor Stroma and MicroenvironmentHari Menon, Rishab Ramapriyan, Taylor R Cushman, et al.
Journal of Immunotherapy and Precision Oncology|April 16, 2025
PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017-2021Mehmet Altan, Dawen Sui, Cai Xu, et al.
Oncoimmunology|December 21, 2023
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseasesPankti Reid, Sabina Sandigursky, Juhee Song, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2020
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLCMark M Awad, Shirish M Gadgeel, Hossein Borghaei, et al.
Pageof 16

Showing results (91-100 of 153) with videos related to

Sort By:
Pageof 16
Clinical Chemistry and Laboratory Medicine|October 26, 2022
Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control studyAntigona Ulndreaj, Davor Brinc, Mehmet Altan, et al.
Journal for Immunotherapy of Cancer|October 14, 2020
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trialJames Welsh, Hari Menon, Dawei Chen, et al.
NPJ Precision Oncology|June 26, 2026
Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biologyJennifer A Marks, Rohan Maniar, Kavitha J Ramchandran, et al.
Clinical Lung Cancer|August 25, 2024
Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective AnalysisFelipe Soto-Lanza, Lydia Glick, Colin Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2021
Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II TrialYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Journal for Immunotherapy of Cancer|June 22, 2023
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitisYousef R Badran, Fangwen Zou, Sienna M Durbin, et al.
Frontiers in Immunology|March 5, 2019
Role of Radiation Therapy in Modulation of the Tumor Stroma and MicroenvironmentHari Menon, Rishab Ramapriyan, Taylor R Cushman, et al.
Journal of Immunotherapy and Precision Oncology|April 16, 2025
PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017-2021Mehmet Altan, Dawen Sui, Cai Xu, et al.
Oncoimmunology|December 21, 2023
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseasesPankti Reid, Sabina Sandigursky, Juhee Song, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2020
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLCMark M Awad, Shirish M Gadgeel, Hossein Borghaei, et al.
Pageof 16